Combining HIIT and n-3 PUFA to Reduce Inflammation and Improve Metabolic Health (HIIT&PUFA)

Combining Fish Oil and Exercise to Improve Obesity-associated Inflammation

The goal of this project is to understand the combined effects of fish oil and exercise in obesity-associated inflammation. The investigators hypothesize that fish oil will improve gut bacteria profiles, which will in turn potentiate the benefits of an exercise program and improve energy utilization and reduce inflammation and metabolic risk.

Study Overview

• Status: Completed
• Conditions: Inflammation; Obesity; Insulin Resistance; Dyslipidemias; Human Microbiome
• Intervention / Treatment: Dietary supplement: Safflower oil; Dietary supplement: Omega-3 polyunsaturated fatty acid; Behavioral: Low-intensity training; Behavioral: High-Intensity Interval Training

Detailed Description

Incidence of obesity continues to increase in the United States and worldwide, making its prevention or reduction a public health priority. Nutrition research that can lead to effective prevention strategies is greatly needed. Inflammation is a major underlying cause for obesity, and it is imperative to understand how anti-inflammatory food sources, such as fish oil, could aid in reducing obesity. Moreover, exercise is effective at reducing systemic inflammation and improving insulin resistance. Both exercise and diet can influence health through changes in the gut microbiome; however, no studies have investigated how together these affect gut microbiome and overall metabolic health. The goal is to understand the combined effects of fish oil and exercise in obesity-associated inflammation. The investigators hypothesize that fish oil will improve gut bacteria profiles, which will in turn potentiate the benefits of an exercise program and improve energy utilization and reduce inflammation and metabolic risk. These studies will provide the foundation for development of novel strategies for obesity, inflammation, dyslipidemia and dysglycemia.

The first aim of this study will focus on determining the combined effects of n-3 PUFA and HIIT on improving metabolic risks such as obesity-related markers of inflammation, dyslipidemia, and insulin resistance.

The investigators will test the hypothesis that n-3 PUFA, in addition to HIIT, will have beneficial effects on energy utilization, as well as obesity-related markers of inflammation, dyslipidemia and insulin resistance.

Aim 2.1: Investigate the influence of n-3 PUFA and HIIT on body weight and composition Aim 2.2: Investigate the influence of n-3 PUFA and HIIT on serum markers associated with obesity Aim 2.3: Investigate influence of n-3 PUFA and HIIT on energy utilization/ markers of insulin resistance

The second aim is to determine the combined effects of n-3 polyunsaturated fatty acids (n-3 PUFA) and high-intensity interval training (HIIT) on improving gut dysbiosis.

The investigators will test the hypothesis that n-3 PUFA supplementation will improve gut microbiota composition and related metabolites, which will result in reduced inflammation and ameliorate the metabolic response to a HIIT exercise intervention in an overweight population.

Aim 1.1: Investigate the influence of n-3 PUFA and exercise on gut microbiota composition

Aim 1.2: Investigate the influence of n-3 PUFA and exercise on microbiota produced metabolites

Participants will be randomly allocated to 1 of 4 treatment groups (n = 120), each balanced for sex, BMI, lipid profile, and dietary intake. The goal is to conduct the study in smaller cohorts, such as 10-15 participants/group (n = 40-60).

Participants will first be allocated to two groups: One group will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) and one group will take placebo (safflower oil, AlaskOmega®, from Organic Technologies Inc.) for 4 weeks of initial supplementation.

Following this, one group from the treatment and one from the placebo group (creating 4 groups: (1) placebo + low-intensity training (LIT); (2) n-3 PUFA + LIT; (3) placebo + HIIT; (4) n-3 PUFA + HIIT) will also participate in a 4 x 4 HIIT exercise (4 intervals for 4 min at 85-95% HRmax with 3min active recovery at 50-70% HRmax) program utilizing cycle ergometers on 3 days/week conducted in the research lab and under investigator supervision for 4 weeks while continuing supplementation.

If not asked to exercise, participants will be instructed to maintain their normal level of physical activity but will participate in a time-matched session of low-intensity training (50% HRmax) on 3 days/week conducted in the research lab and under investigator supervision.

All participants will wear a heart rate monitor (Polar H10) provided by TTU throughout the training (HIIT and LIT) to monitor exertion level.

Capsules will be administered in a double-blind fashion and will be identical in appearance. Participants will visit the clinic to pick up capsules. To ensure compliance, subjects will be reminded via phone (text message or phone call based on participant preference) to take their capsules and counts will be conducted when they come in for study visits.

As with any acute metabolic or physiological improvements, beneficial effects of exercise on bacterial taxa and resultant metabolite production are quickly reversed with detraining. Thus, it is of interest to determine if fish consumption can ameliorate the negative metabolic and gut effects of detraining.

At the end of the 4-week intervention (week 8), participants will cease engaging in HIIT or LIT for a 2-week detraining period. Participants will continue taking their assigned supplements.

• Study Type: Interventional
• Enrollment (Actual): 129
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Texas
    • Lubbock, Texas, United States, 79406
      • Texas Tech Kinesiology Building

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• 18-65 years old
• Overweight/ Obese (BMI ≥ 25 to ≤ 40 kg/m2)
• Elevated Triglycerides (>150 mg/dL)
• Prediabetes (fasting blood glucose 100 to 125 mg/dl)

Exclusion Criteria:

• Diagnosed with Diabetes or liver disease.
• Taking BP or diabetes medications.
• Received antibiotics medications in the last 6 months.
• Pregnant/ lactating/ Irregular menstrual cycle/ menopausal.
• Currently following a formal/ structured weight loss program.
• Currently taking fish oil.
• Do not have access to smart phone/ computer with internet access.
• Exercise ≥ 1 time/week or a moderate-high score on the International Physical Activity Questionnaire.
• Feeling uncomfortable riding bike for 30 minutes.
• Claustrophobic or unable to stay under the hood for metabolic testing.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo & Flexibility Training (Control); Subjects will take placebo (safflower oil, AlaskOmega®) for an initial supplementation period of 4 weeks. Participants will continue supplementation and will also engage in low-intensity training (control group) for 30 minutes 3 times/week for 4 weeks. All exercise sessions will be performed on a stationary bike and conducted under investigator supervision. Participants will continue supplementation and will cease low-intensity training for a 2 week follow-up period.	Dietary supplement: Safflower oil; 4 grams safflower oil (AlaskOmega®) per day; Other Names: Placebo; Behavioral: Low-intensity training; A low-intensity training exercise program 3 days/week for 4 weeks. This will include consistently cycling at 50% HRmax for 30 min.
Active Comparator: Placebo & High-Intensity Interval Training; Subjects will take placebo (safflower oil, AlaskOmega®) for an initial supplementation period of 4 weeks. Participants will continue supplementation and will also engage in a 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 4 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max . All exercise sessions will be performed on a stationary bike and conducted under investigator supervision. Participants will continue supplementation and cease HIIT training for a 2 week follow-up period.	Dietary supplement: Safflower oil; 4 grams safflower oil (AlaskOmega®) per day; Other Names: Placebo; Behavioral: High-Intensity Interval Training; A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 4 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.; Other Names: HIIT
Active Comparator: n-3 PUFA & Flexibility Training (Control); Subjects will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for an initial supplementation period of 4 weeks. Participants will continue supplementation and will also engage in low-intensity training (control group) for 30 minutes 3 times/week for 4 weeks. All exercise sessions will be performed on a stationary bike and conducted under investigator supervision. Participants will continue supplementation and cease low-intensity training for a 2 week follow-up period.	Dietary supplement: Omega-3 polyunsaturated fatty acid; 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA); Other Names: AlaskOmega; Behavioral: Low-intensity training; A low-intensity training exercise program 3 days/week for 4 weeks. This will include consistently cycling at 50% HRmax for 30 min.
Experimental: n-3 PUFA & High-Intensity Interval Training; Subjects will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for an initial supplementation period of 4 weeks. Participants will continue supplementation and will also engage in a 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 4 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max . All exercise sessions will be performed on a stationary bike and conducted under investigator supervision. Participants will continue supplementation and cease low-intensity training for a 2 week follow-up period.	Dietary supplement: Omega-3 polyunsaturated fatty acid; 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA); Other Names: AlaskOmega; Behavioral: High-Intensity Interval Training; A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 4 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.; Other Names: HIIT

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Change from Baseline in Serum high-sensitivity C-reactive protein at 4 weeks	Serum high-sensitivity C-reactive protein (hs-CRP; mg/L)	Post-Supplementation at week 4
Mean Change from Baseline in Interleukin (IL)-6 at 4 weeks	Interleukin (IL)-6 (pg/mL)	Post-Supplementation at week 4
Mean Change from Baseline in Interleukin (IL)-10 at 4 weeks	Interleukin (IL)-10 (pg/mL)	Post-Supplementation at week 4
Mean Change from Baseline in Monocyte chemoattractant protein-1 at 4 weeks	Monocyte chemoattractant protein-1 (MCP-1; pg/mL)	Post-Supplementation at week 4
Mean Change from Baseline in Tumor necrosis factor at 4 weeks	Tumor necrosis factor (TNF)-alpha (pg/mL)	Post-Supplementation at week 4
Mean Change from Baseline in Total Cholesterol at 4 weeks	Total cholesterol (mg/dL)	Post-Supplementation at week 4
Mean Change from Baseline in High-density lipoprotein (HDL)at 4 weeks	High-density lipoprotein (HDL) (mg/dL)	Post-Supplementation at week 4
Mean Change from Baseline in Non-high-density lipoprotein (Non-HDL) at 4 weeks	Non-high-density lipoprotein (Non-HDL) (mg/dL)	Post-Supplementation at week 4
Mean Change from Baseline in Low-density lipoprotein (LDL) at 4 weeks	Low-density lipoprotein (LDL) (mg/dL)	Post-Supplementation at week 4
Mean Change from Baseline in Very-low-density lipoprotein (VLDL) at 4 weeks	Very-low-density lipoprotein (VLDL) (mg/dL)	Post-Supplementation at week 4
Mean Change from Baseline in Triglycerides at 4 weeks	Triglycerides (mg/dL).	Post-Supplementation at week 4
Mean Change from Baseline in Total/HDL cholesterol at 4 weeks	Total/HDL cholesterol (mg/dL)	Post-Supplementation at week 4
Mean Change from Baseline in Fasting blood glucose at 4 weeks	Fasting blood glucose (mg/dL)	Post-supplementation at week 4
Mean Change from Baseline in Insulin at 4 weeks	Insulin (μU/mL)	Post-supplementation at week 4
Mean Change from Baseline in Total Body Fat Percentage at 4 weeks	Total Body Fat Percentage (%BF): The percent of the body that is composed of fat. This will change based on the amount of fat there is as well as the amount of lean mass there is.	Post-Supplementation at week 4
Mean Change from Baseline in Body Weight at 4 weeks	Body weight (kilograms)	Post-Supplementation at week 4
Mean Change from Baseline in Skeletal Muscle Mass Percentage at 4 weeks	Skeletal Muscle Mass Percentage (%SMM): The percent of the body that is composed of skeletal muscle. Like %BF, this number is relative to total mass.	Post-Supplementation at week 4
Mean Change from Baseline in Serum high-sensitivity C-reactive protein at 8 weeks	Serum high-sensitivity C-reactive protein (hs-CRP; mg/L)	Post-Intervention at week 8
Mean Change from Baseline in Monocyte chemoattractant protein-1 at 8 weeks	Monocyte chemoattractant protein-1 (MCP-1; pg/mL)	Post-Intervention at week 8
Mean Change from Baseline in Interleukin (IL)-6 at 8 weeks	Interleukin (IL)-6 (pg/mL)	Post-Intervention at week 8
Mean Change from Baseline in Interleukin (IL)-10 at 8 weeks	Interleukin (IL)-10 (pg/mL)	Post-Intervention at week 8
Mean Change from Baseline in Tumor necrosis factor (TNF) at 8 weeks	Tumor necrosis factor (TNF)-alpha (pg/mL)	Post-Intervention at week 8
Mean Change from Baseline in Total Cholesterol at 8 weeks	Total Cholesterol (mg/dL)	Post-Intervention at week 8
Mean Change from Baseline in High-density lipoprotein (HDL) at 8 weeks	High-density lipoprotein (HDL) (mg/dL)	Post-Intervention at week 8
Mean Change from Baseline in Non-high-density lipoprotein (Non-HDL) at 8 weeks	Non-high-density lipoprotein (Non-HDL) (mg/dL)	Post-intervention at week 8
Mean Change from Baseline in Low-density lipoprotein (LDL) at 8 weeks	Low-density lipoprotein (LDL) (mg/dL)	Post-Intervention at week 8
Mean Change from Baseline in Very-low-density lipoprotein (VLDL) at 8 weeks	Very-low-density lipoprotein (VLDL) (mg/dL)	Post-Intervention at week 8
Mean Change from Baseline in Triglycerides at 8 weeks	Triglycerides (mg/dL).	Post-Intervention at week 8
Mean Change from Baseline in total/HDL cholesterol at 8 weeks	Total/HDL cholesterol (mg/dL)	Post-Intervention at week 8
Mean Change from Baseline in Fasting blood glucose at 8 weeks	Fasting blood glucose (mg/dL)	Post-Intervention at week 8
Mean Change from Baseline in Oral glucose tolerance test (OGTT) at 8 weeks	Oral glucose tolerance test (OGTT). Following ingestion of 75 g oral glucose, blood samples will be drawn every 5-10 minutes for the first 30 minutes then every 30 minutes for the next 90 minutes.	Post-Intervention at week 8
Mean Change from Baseline in Insulin at 8 weeks	Insulin (μU/mL)	Post-Intervention at week 8
Mean Change from Baseline in Body Weight at 8 weeks	Body weight (kilograms)	Post-Intervention at week 8
Mean Change from Baseline in Total Body Fat Percentage at 8 weeks	Total Body Fat Percentage (%BF): The percent of the body that is composed of fat. This will change based on the amount of fat there is as well as the amount of lean mass there is.	Post-Intervention at week 8
Mean Change from Baseline in Skeletal Muscle Mass Percentage at 8 weeks	Skeletal Muscle Mass Percentage (%SMM): The percent of the body that is composed of skeletal muscle. Like %BF, this number is relative to total mass.	Post-Intervention at week 8
Mean Change from Baseline in Serum high-sensitivity C-reactive protein at 10 weeks	Serum high-sensitivity C-reactive protein (hs-CRP; mg/L)	Post-Detraining at week 10
Mean Change from Baseline in Interleukin (IL)-6 at 10 weeks	Interleukin (IL)-6 (pg/mL)	Post-Detraining at week 10
Mean Change from Baseline in Interleukin (IL)-10 at 10 weeks	Interleukin (IL)-10 (pg/mL)	Post-Detraining at week 10
Mean Change from Baseline in Tumor necrosis factor (TNF) at 10 weeks	Tumor necrosis factor (TNF)-alpha (pg/mL)	Post-Detraining at week 10
Mean Change from Baseline in Monocyte chemoattractant protein-1 at 10 weeks	Monocyte chemoattractant protein-1 (MCP-1; pg/mL)	Post-Detraining at week 10
Mean Change from Baseline in Total Cholesterol at 10 weeks	Total Cholesterol (mg/dL)	Post-Detraining at week 10
Mean Change from Baseline in High-density lipoprotein (HDL) at 10 weeks	High-density lipoprotein (HDL) (mg/dL)	Post-Detraining at week 10
Mean Change from Baseline in Non-high-density lipoprotein (Non-HDL) at 10 weeks	Non-high-density lipoprotein (Non-HDL) (mg/dL)	Post-Detraining at week 10
Mean Change from Baseline in Low-density lipoprotein (LDL) at 10 weeks	Low-density lipoprotein (LDL)(mg/dL)	Post-Detraining at week 10
Mean Change from Baseline in Very-low-density lipoprotein (VLDL) at 10 weeks	Very-low-density lipoprotein (VLDL) (mg/dL)	Post-Detraining at week 10
Mean Change from Baseline in Total/HDL cholesterol at 10 weeks	Total/HDL cholesterol (mg/dL)	Post-Detraining at week 10
Mean Change from Baseline in Triglycerides at 10 weeks	Triglycerides (mg/dL)	Post-Detraining at week 10
Mean Change from Baseline in Insulin at 10 weeks	Insulin (μU/mL)	Post-Detraining at week 10
Mean Change from Baseline in Fasting blood glucose at 10 weeks	Fasting blood glucose (mg/dL)	Post-Detraining at week 10
Mean Change from Baseline in Skeletal Muscle Mass Percentage at 10 weeks	Skeletal Muscle Mass Percentage (%SMM): The percent of the body that is composed of skeletal muscle. Like %BF, this number is relative to total mass.	Post-Detraining at week 10
Mean Change from Baseline in Body weight at 10 weeks	Body weight (kilograms)	Post-Detraining at week 10
Mean Change from Baseline in Total Body Fat Percentage at 10 weeks	Total Body Fat Percentage (%BF): The percent of the body that is composed of fat. This will change based on the amount of fat there is as well as the amount of lean mass there is.	Post-Detraining at week 10
Mean Change from Post-Supplementation in Serum high-sensitivity C-reactive protein at 8 weeks	Serum high-sensitivity C-reactive protein (hs-CRP; mg/L)	Post-Intervention at week 8
Mean Change from Post-Supplementation in Interleukin (IL)-6 at 8 weeks	Interleukin (IL)-6 (pg/mL)	Post-Intervention at week 8
Mean Change from Post-Supplementation in Interleukin (IL)-10 at 8 weeks	Interleukin (IL)-10 (pg/mL)	Post-Intervention at week 8
Mean Change from Post-Supplementation in Monocyte chemoattractant protein-1 at 8 weeks	Monocyte chemoattractant protein-1 (MCP-1; pg/mL)	Post-Intervention at week 8
Mean Change from Post-Supplementation in Tumor necrosis factor (TNF) at 8 weeks	Tumor necrosis factor (TNF)-alpha (pg/mL)	Post-Intervention at week 8
Mean Change from Post-Supplementation in Total Cholesterol at 8 weeks	Total Cholesterol (mg/dL)	Post-Intervention at week 8
Mean Change from Post-Supplementation in Total/HDL cholesterol at 8 weeks	Total/HDL cholesterol (mg/dL)	Post-Intervention at week 8
Mean Change from Post-Supplementation in High-density lipoprotein (HDL) at 8 weeks	High-density lipoprotein (HDL) (mg/dL)	Post-Intervention at week 8
Mean Change from Post-Supplementation in Non-high-density lipoprotein (Non-HDL) at 8 weeks	Non-high-density lipoprotein (Non-HDL) (mg/dL)	Post-Intervention at week 8
Mean Change from Post-Supplementation in Low-density lipoprotein (LDL) at 8 weeks	Low-density lipoprotein (LDL) (mg/dL)	Post-Intervention at week 8
Mean Change from Post-Supplementation in Very-low-density lipoprotein (VLDL) at 8 weeks	Very-low-density lipoprotein (VLDL) (mg/dL)	Post-Intervention at week 8
Mean Change from Post-Supplementation in Triglycerides at 8 weeks	Triglycerides (mg/dL)	Post-Intervention at week 8
Mean Change from Post-Supplementation in Insulin at 8 weeks	Insulin (μU/mL)	Post-Intervention at week 8
Mean Change from Post-Supplementation in Fasting blood glucose at 8 weeks	Fasting blood glucose (mg/dL)	Post-Intervention at week 8
Mean Change from Post-Supplementation in Body weight at 8 weeks	Body weight (kilograms)	Post-Intervention at week 8
Mean Change from Post-Supplementation in Total Body Fat Percentage at 8 weeks	Total Body Fat Percentage (%BF): The percent of the body that is composed of fat. This will change based on the amount of fat there is as well as the amount of lean mass there is.	Post-Intervention at week 8
Mean Change from Post-Intervention in Serum high-sensitivity C-reactive protein at 10 weeks	Serum high-sensitivity C-reactive protein (hs-CRP; mg/L)	Post-Detraining at week 10
Mean Change from Post-Intervention in Tumor Necrosis Factor (TNF) at 10 weeks	Tumor necrosis factor (TNF)-alpha (pg/mL)	Post-Detraining at week 10
Mean Change from Post-Intervention in Interleukin (IL)-6 at 10 weeks	Interleukin (IL)-6 (pg/mL)	Post-Detraining at week 10
Mean Change from Post-Intervention in Interleukin (IL)-10 at 10 weeks	Interleukin (IL)-10 (pg/mL)	Post-Detraining at week 10
Mean Change from Post-Intervention in Monocyte Chemoattractant Protein-1 at 10 weeks	Monocyte chemoattractant protein-1 (MCP-1; pg/mL)	Post-Detraining at week 10
Mean Change from Post-Intervention in Total Cholesterol at 10 weeks	Total Cholesterol (mg/dL)	Post-Detraining at week 10
Mean Change from Post-Intervention in High-density lipoprotein (HDL) at 10 weeks	High-density lipoprotein (HDL) (mg/dL)	Post-Detraining at week 10
Mean Change from Post-Intervention in Non-high-density lipoprotein (Non-HDL) at 10 weeks	Non-high-density lipoprotein (Non-HDL) (mg/dL)	Post-Detraining at week 10
Mean Change from Post-Intervention in Low-density lipoprotein (LDL) at 10 weeks	Low-density lipoprotein (LDL) (mg/dL)	Post-Detraining at week 10
Mean Change from Post-Intervention in Very-low-density lipoprotein (VLDL) at 10 weeks	Very-low-density lipoprotein (VLDL) (mg/dL)	Post-Detraining at week 10
Mean Change from Post-Intervention in Total/HDL cholesterol at 10 weeks	Total/HDL cholesterol (mg/dL)	Post-Detraining at week 10
Mean Change from Post-Intervention in Triglycerides at 10 weeks	Triglycerides (mg/dL)	Post-Detraining at week 10
Mean Change from Post-Intervention in Insulin at 10 weeks	Insulin (μU/mL)	Post-Detraining at week 10
Mean Change from Post-Intervention in Fasting blood glucose at 10 weeks	Fasting blood glucose (mg/dL)	Post-Detraining at week 10
Mean Change from Post-Intervention in Body weight at 10 weeks	Body weight (kilograms)	Post-Detraining at week 10
Mean Change from Post-Intervention in Total Body Fat Percentage at 10 weeks	Total Body Fat Percentage (%BF): The percent of the body that is composed of fat. This will change based on the amount of fat there is as well as the amount of lean mass there is.	Post-Detraining at week 10
Mean Change from Post-Intervention in Skeletal Muscle Mass Percentage at 10 weeks	Skeletal Muscle Mass Percentage (%SMM): The percent of the body that is composed of skeletal muscle. Like %BF, this number is relative to total mass.	Post-Detraining at week 10

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Change from Baseline in Bacterial Profile at 4 weeks	Fecal Microbial DNA (16s Sequencing)	Post-Supplementation at week 4
Mean Change from Baseline in Serum Acetate Profile at 4 weeks	Serum Acetate (SCFA: gas chromatography analysis)	Post-Supplementation at week 4
Mean Change from Baseline in Fecal acetate Profile at 4 weeks	Fecal acetate (SCFA: in fecal samples by liquid chromatography tandem mass spectrometry (LC-MS/MS))	Post-Supplementation at week 4
Mean Change from Baseline in Propionate Profile at 4 weeks	Propionate (liquid chromatography tandem mass spectrometry (LC-MS/MS))	Post-Supplementation at week 4
Mean Change from Baseline in Butyrate Profile at 4 weeks	Butyrate (liquid chromatography tandem mass spectrometry (LC-MS/MS))	Post-Supplementation at week 4
Mean Change from Baseline in Markers of Serum lipopolysaccharides at 4 weeks	Serum lipopolysaccharides (LPS, ng/ml)	Post-Supplementation at week 4
Mean Change from Baseline in Markers of Serum lipopolysaccharides-binding protein at 4 weeks	Serum lipopolysaccharides-binding protein (LBP, pg/ml)	Post-Supplementation at week 4
Mean Change from Baseline in Bacterial Profile at 8 weeks	Fecal Microbial DNA (16s Sequencing)	Post-Intervention at week 8
Mean Change from Baseline in Serum Acetate Profile at 8 weeks	Serum Acetate (SCFA: gas chromatography analysis)	Post-Intervention at week 8
Mean Change from Baseline in Fecal acetate Profile at 8 weeks	Fecal acetate (SCFA: in fecal samples by liquid chromatography tandem mass spectrometry (LC-MS/MS))	Post-Intervention at week 8
Mean Change from Baseline in Propionate Profile at 8 weeks	Propionate (liquid chromatography tandem mass spectrometry (LC-MS/MS))	Post-Intervention at week 8
Mean Change from Baseline in Butyrate Profile at 8 weeks	Butyrate (liquid chromatography tandem mass spectrometry (LC-MS/MS))	Post-Intervention at week 8
Mean Change from Baseline in Markers of Serum lipopolysaccharides at 8 weeks	Serum lipopolysaccharides (LPS, ng/ml)	Post-Intervention at week 8
Mean Change from Baseline in Markers of Serum lipopolysaccharides-binding protein at 8 weeks	Serum lipopolysaccharides-binding protein (LBP, pg/ml)	Post-Intervention at week 8
Mean Change from Baseline in Serum Acetate Profile at 10 weeks	Serum Acetate (SCFA: gas chromatography analysis)	Post-Detraining at week 10
Mean Change from Baseline in Fecal acetate Profile at 10 weeks	Fecal acetate (SCFA: in fecal samples by liquid chromatography tandem mass spectrometry (LC-MS/MS))	Post-Detraining at week 10
Mean Change from Baseline in Bacterial Profile at 10 weeks	Fecal Microbial DNA (16s Sequencing)	Post-Detraining at week 10
Mean Change from Baseline in Propionate Profile at 10 weeks	Propionate (liquid chromatography tandem mass spectrometry (LC-MS/MS))	Post-Detraining at week 10
Mean Change from Baseline in Butyrate Profile at 10 weeks	Butyrate (liquid chromatography tandem mass spectrometry (LC-MS/MS))	Post-Detraining at week 10
Mean Change from Baseline in Markers of Serum lipopolysaccharides at 10 weeks	Serum lipopolysaccharides (LPS, ng/ml)	Post-Detraining at week 10
Mean Change from Baseline in Markers of Serum lipopolysaccharides-binding protein at 10 weeks	Serum lipopolysaccharides-binding protein (LBP, pg/ml)	Post-Detraining at week 10
Mean Change from Post-Supplementation in Bacterial Profile at 8 weeks	Fecal Microbial DNA (16s Sequencing)	Post-Intervention at week 8
Mean Change from Post-Supplementation in Serum Acetate Profile at 8 weeks	Serum Acetate (SCFA: gas chromatography analysis)	Post-Intervention at week 8
Mean Change from Post-Supplementation in Fecal acetate Profile at 8 weeks	Fecal acetate (SCFA: in fecal samples by liquid chromatography tandem mass spectrometry (LC-MS/MS))	Post-Intervention at week 8
Mean Change from Post-Supplementation in Propionate Profile at 8 weeks	Propionate (liquid chromatography tandem mass spectrometry (LC-MS/MS))	Post-Intervention at week 8
Mean Change from Post-Supplementation in Butyrate Profile at 8 weeks	Butyrate (liquid chromatography tandem mass spectrometry (LC-MS/MS))	Post-Intervention at week 8
Mean Change from Post-Supplementation in Markers of Serum lipopolysaccharides at 8 weeks	Serum lipopolysaccharides (LPS, ng/ml)	Post-Intervention at week 8
Mean Change from Post-Supplementation in Markers of Serum lipopolysaccharides-binding protein at 8 weeks	Serum lipopolysaccharides-binding protein (LBP, pg/ml)	Post-Intervention at week 8
Mean Change from Post-Intervention in Bacterial Profile at 10 weeks	Fecal Microbial DNA (16s Sequencing)	Post-Detraining at week 10
Mean Change from Post-Intervention in Serum Acetate Profile at 10 weeks	Serum Acetate (SCFA: gas chromatography analysis)	Post-Detraining at week 10
Mean Change from Post-Intervention in Fecal acetate Profile at 10 weeks	Fecal acetate (SCFA: in fecal samples by liquid chromatography tandem mass spectrometry (LC-MS/MS))	Post-Detraining at week 10
Mean Change from Post-Intervention in Propionate Profile at 10 weeks	Propionate (liquid chromatography tandem mass spectrometry (LC-MS/MS))	Post-Detraining at week 10
Mean Change from Post-Intervention in Butyrate Profile at 10 weeks	Butyrate (liquid chromatography tandem mass spectrometry (LC-MS/MS))	Post-Detraining at week 10
Mean Change from Post-Intervention in Markers of Serum lipopolysaccharides at 10 weeks	Serum lipopolysaccharides (LPS, ng/ml)	Post-Detraining at week 10
Mean Change from Post-Intervention in Markers of Serum lipopolysaccharides-binding protein at 10 weeks	Serum lipopolysaccharides-binding protein (LBP, pg/ml)	Post-Detraining at week 10

Collaborators and Investigators

• Sponsor: Texas Tech University
• Collaborators: University of Houston; Texas Tech University Health Sciences Center
• Investigators: Principal Investigator: Kembra D Albracht-Schulte, Ph.D, Texas Tech University

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2022
• Primary Completion (Actual): December 31, 2024
• Study Completion (Actual): December 31, 2024

Study Registration Dates

• First Submitted: December 14, 2021
• First Submitted That Met QC Criteria: March 15, 2022
• First Posted (Actual): March 25, 2022

Study Record Updates

• Last Update Posted (Estimated): September 11, 2025
• Last Update Submitted That Met QC Criteria: September 4, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Nutrition Disorders; Metabolic Diseases; Overnutrition; Body Weight; Glucose Metabolism Disorders; Hyperinsulinism; Overweight; Lipid Metabolism Disorders; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Obesity; Inflammation; Insulin Resistance; Dyslipidemias; Motor Activity; Movement; Musculoskeletal Physiological Phenomena; Musculoskeletal and Neural Physiological Phenomena; Substandard Drugs; Pharmaceutical Preparations; Fatty Acids; Lipids; Food; Diet, Food, and Nutrition; Physiological Phenomena; Food and Beverages; Physical Conditioning, Human; Plant Preparations; Biological Products; Complex Mixtures; Exercise; Eicosanoids; Fatty Acids, Unsaturated; Plant Oils; Oils; Dietary Fats; Fats; Fatty Acids, Omega-3; Dietary Fats, Unsaturated; Fish Oils; Fats, Unsaturated; Counterfeit Drugs; High-Intensity Interval Training; Eicosapentaenoic Acid; Safflower Oil
• Other Study ID Numbers: 2019-07195; GRANT12908084 (Other Grant/Funding Number: USDA NIFA)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No